Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

iconic brands

- PMLiVE

Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes

The insulin is designed as an alternative to daily basal insulin

- PMLiVE

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

- PMLiVE

Novo Nordisk elects employee representatives to Board of Directors

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026

- PMLiVE

Novo Nordisk to invest 432m euros to expand manufacturing facility in Ireland

Construction is expected to be completed in phases from the end of 2027 into 2028

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic

The reduction in price to $675 will take effect at the beginning of next year

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030

The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China

- PMLiVE

Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity

Obesity affects approximately 15 million people in the UK

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links